Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miltefosine and Paromomycin for Visceral Leishmaniasis
NCT03129646Phase 3Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Jan 2018
- Primary completion
- Dec 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of miltefosine in visceral leishmaniasis (VL), sponsored by Drugs for Neglected Diseases initiative. Started Jan 2018; status: completed.
02
Drugs
miltefosine
03
Conditions
visceral leishmaniasis (VL)
Beyond the preview
Go deeper on NCT03129646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03129646.